Aberrant DNA methylation in lung cancer: Biological and clinical implications

Sabine Zöchbauer-Müller, John D. Minna, Adi F. Gazdar

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Genetic abnormalities of proto-oncogenes and tumor suppressor genes are well-known changes that are frequently involved in lung cancer pathogenesis. However, another mechanism for inactivation of tumor suppressor genes is coming more and more into focus. Epigenetic inactivation of certain tumor suppressor genes by aberrant promoter methylation is frequently observed in lung carcinomas and seems to play an important role in the pathogenesis of this tumor type. While genetic abnormalities are associated with changes in DNA sequence, epigenetic events may lead to changes in gene expression that occur without changes in DNA sequence. Recent findings demonstrate that aberrant methylation can also be detected in the smoking-damaged bronchial epithelium from cancer-free heavy smokers, suggesting that aberrant methylation might be an ideal candidate biomarker for lung cancer risk assessment and monitoring of chemoprevention trials. Moreover, in vitro studies demonstrate that methylation can be reversed by demethylating agents resulting in gene re-expression. This concept is currently under investigation in clinical trials. In summary, recent studies demonstrate that aberrant methylation may be the most common mechanism of inactivating cancer-related genes in lung cancer, occurs already in smoking-damaged bronchial epithelium from cancer-free individuals, can be reversed in vitro by demethylating agents, and may be a useful biomarker for lung cancer risk assessment.

Original languageEnglish (US)
Pages (from-to)451-457
Number of pages7
JournalOncologist
Volume7
Issue number5
DOIs
StatePublished - 2002

Fingerprint

DNA Methylation
Methylation
Lung Neoplasms
Tumor Suppressor Genes
Epigenomics
Epithelium
Biomarkers
Smoking
Gene Expression
Neoplasms
Proto-Oncogenes
Neoplasm Genes
Chemoprevention
Clinical Trials
Carcinoma
Lung
In Vitro Techniques

Keywords

  • Lung cancer
  • Methylation
  • Preneoplastic lesion
  • Risk assessment
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Aberrant DNA methylation in lung cancer : Biological and clinical implications. / Zöchbauer-Müller, Sabine; Minna, John D.; Gazdar, Adi F.

In: Oncologist, Vol. 7, No. 5, 2002, p. 451-457.

Research output: Contribution to journalArticle

Zöchbauer-Müller, Sabine ; Minna, John D. ; Gazdar, Adi F. / Aberrant DNA methylation in lung cancer : Biological and clinical implications. In: Oncologist. 2002 ; Vol. 7, No. 5. pp. 451-457.
@article{fc1e28a50c2845a8a987d70362a1a562,
title = "Aberrant DNA methylation in lung cancer: Biological and clinical implications",
abstract = "Genetic abnormalities of proto-oncogenes and tumor suppressor genes are well-known changes that are frequently involved in lung cancer pathogenesis. However, another mechanism for inactivation of tumor suppressor genes is coming more and more into focus. Epigenetic inactivation of certain tumor suppressor genes by aberrant promoter methylation is frequently observed in lung carcinomas and seems to play an important role in the pathogenesis of this tumor type. While genetic abnormalities are associated with changes in DNA sequence, epigenetic events may lead to changes in gene expression that occur without changes in DNA sequence. Recent findings demonstrate that aberrant methylation can also be detected in the smoking-damaged bronchial epithelium from cancer-free heavy smokers, suggesting that aberrant methylation might be an ideal candidate biomarker for lung cancer risk assessment and monitoring of chemoprevention trials. Moreover, in vitro studies demonstrate that methylation can be reversed by demethylating agents resulting in gene re-expression. This concept is currently under investigation in clinical trials. In summary, recent studies demonstrate that aberrant methylation may be the most common mechanism of inactivating cancer-related genes in lung cancer, occurs already in smoking-damaged bronchial epithelium from cancer-free individuals, can be reversed in vitro by demethylating agents, and may be a useful biomarker for lung cancer risk assessment.",
keywords = "Lung cancer, Methylation, Preneoplastic lesion, Risk assessment, Tumor suppressor gene",
author = "Sabine Z{\"o}chbauer-M{\"u}ller and Minna, {John D.} and Gazdar, {Adi F.}",
year = "2002",
doi = "10.1634/theoncologist.7-5-451",
language = "English (US)",
volume = "7",
pages = "451--457",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Aberrant DNA methylation in lung cancer

T2 - Biological and clinical implications

AU - Zöchbauer-Müller, Sabine

AU - Minna, John D.

AU - Gazdar, Adi F.

PY - 2002

Y1 - 2002

N2 - Genetic abnormalities of proto-oncogenes and tumor suppressor genes are well-known changes that are frequently involved in lung cancer pathogenesis. However, another mechanism for inactivation of tumor suppressor genes is coming more and more into focus. Epigenetic inactivation of certain tumor suppressor genes by aberrant promoter methylation is frequently observed in lung carcinomas and seems to play an important role in the pathogenesis of this tumor type. While genetic abnormalities are associated with changes in DNA sequence, epigenetic events may lead to changes in gene expression that occur without changes in DNA sequence. Recent findings demonstrate that aberrant methylation can also be detected in the smoking-damaged bronchial epithelium from cancer-free heavy smokers, suggesting that aberrant methylation might be an ideal candidate biomarker for lung cancer risk assessment and monitoring of chemoprevention trials. Moreover, in vitro studies demonstrate that methylation can be reversed by demethylating agents resulting in gene re-expression. This concept is currently under investigation in clinical trials. In summary, recent studies demonstrate that aberrant methylation may be the most common mechanism of inactivating cancer-related genes in lung cancer, occurs already in smoking-damaged bronchial epithelium from cancer-free individuals, can be reversed in vitro by demethylating agents, and may be a useful biomarker for lung cancer risk assessment.

AB - Genetic abnormalities of proto-oncogenes and tumor suppressor genes are well-known changes that are frequently involved in lung cancer pathogenesis. However, another mechanism for inactivation of tumor suppressor genes is coming more and more into focus. Epigenetic inactivation of certain tumor suppressor genes by aberrant promoter methylation is frequently observed in lung carcinomas and seems to play an important role in the pathogenesis of this tumor type. While genetic abnormalities are associated with changes in DNA sequence, epigenetic events may lead to changes in gene expression that occur without changes in DNA sequence. Recent findings demonstrate that aberrant methylation can also be detected in the smoking-damaged bronchial epithelium from cancer-free heavy smokers, suggesting that aberrant methylation might be an ideal candidate biomarker for lung cancer risk assessment and monitoring of chemoprevention trials. Moreover, in vitro studies demonstrate that methylation can be reversed by demethylating agents resulting in gene re-expression. This concept is currently under investigation in clinical trials. In summary, recent studies demonstrate that aberrant methylation may be the most common mechanism of inactivating cancer-related genes in lung cancer, occurs already in smoking-damaged bronchial epithelium from cancer-free individuals, can be reversed in vitro by demethylating agents, and may be a useful biomarker for lung cancer risk assessment.

KW - Lung cancer

KW - Methylation

KW - Preneoplastic lesion

KW - Risk assessment

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=0036411838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036411838&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.7-5-451

DO - 10.1634/theoncologist.7-5-451

M3 - Article

C2 - 12401908

AN - SCOPUS:0036411838

VL - 7

SP - 451

EP - 457

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 5

ER -